DV
Dividend Vision

NTLA — Intellia Therapeutics, Inc.

Intellia Therapeutics, Inc. (NTLA)

Total return is -46.1% over the past 10.3 years, 391.4 points behind SPY at 345.3%. Its deepest 1-year drawdown was 71.3%.

This is an individual stock rather than an ETF—Intellia Therapeutics is a biotechnology company focused on CRISPR gene-editing therapies. As a single equity security, it does not pay dividends and lacks the diversification, expense ratio, or distribution frequency characteristics typical of ETFs. The stock appeals primarily to growth-oriented investors with higher risk tolerance who are interested in exposure to emerging gene-therapy technologies, rather than income-focused dividend investors.

NTLA key facts

Asset type
Stock
Asset class
Equity
Inception date
05/06/2016
Distribution frequency
None
Last close
$11.91
Market cap
$1,657,698,688
Average volume
2359200.0
Beta
1.794
Payout ratio
0.0
Forward P/E
0.0
EPS
$-3.26